Bristol-Myers Squibb Co. (BMY)
Loading...
Symbols:
BMY Forum Topics
- All Comments on BMY
- General Discussion on BMY
- Fannie & Freddie Bailout? - Fast Money Recap (9/5/08) [view article]
- 5 Potential Buyout Targets in Biotech - Barron's [view article]
- Big Pharma Pipeline: Why So Dry? [view article]
- Biotech Outlook: M&A Will Continue [view article]
- China's Hepatitis B Market to Double by 2012 [view article]
- Time to Invest in Pharmaceuticals? [view article]
- Five Biopharma Companies Drop on Negative Drug News [view article]
- The Top Dividend Paying ETFs and Stocks [view article]
- Imclone Systems: No Shame, No Gain [view article]
- Updates on the Healthcare/Biotech Mergers [view article]
- Companies With Recent, Innovative Product Approvals vs. Healthcare ETFs [view article]
- Big Pharma’s Healthy Appetite for Acquisitions [view article]
loading ...Recent BMY Articles
- Merger Watch: ImClone Systems - Bristol Myers Squibb
- Eli Lilly's Brewing Battle With Bristol-Myers
- Fannie & Freddie Bailout? - Fast Money Recap (9/5/08)
- Big Pharma Pipeline: Why So Dry?
- Biotech Outlook: M&A Will Continue
- China's Hepatitis B Market to Double by 2012
- Five Biopharma Companies Drop on Negative Drug News
- 2008 Q2 Portfolio Holdings: Berkowitz, Rodriguez & Pabrai
- Bristol-Myers Ponies Up for Elotuzumab
- AstraZeneca Gives FluMist Spray a Shot in the Arm
- Full List of Articles »
Trading Center
Hedge Fund Jobs
Job Seekers: Search jobs by category, get job alerts by email or live feed, apply online See full list of jobs »
Employers: See all recruitment options, get applications online or by email Post a job »
r
Stay Clear of Traditional Asset Classes [view article]
MIke -Fantastic article. For those reading this anew, like I just did, the Dow was off 400 today, oil spiked $13 in the last two days to an all time high of $138 and SKF was up 10% TODAY ALONE to $122.
My only comment is to say that Mike you are, indeed, conservative. This "credit crisis" (and why do we call it that? That's like the drunk saying I have a stopping, not a drinking, problem) has already derailed the US economy and we are only beginning to feel its effects.
Remember the good old days - you know, February -when you could buy gas for $3.00? And when a loaf of bread cost $2.00 instead of its current $4.00? Well, remember them fondly, because until the Fed keeps propping up the illiquid banking system and Congress keeps propping up the insolvent housing market regular guys like you and me are going to take it in the shorts at the pump and the register.
But you know what? Nobody cares. At least nobody in any position to do anything about it, at least not that I can see. The entire inflation problem could be solved overnight if Bernenke would grow some stones and say "OK - enough. Sorry, bankers, sorry 2% of Americans with an underwater ARM, sorry Wall St.; inflation is killing this country and we are raising rates 100 BPs every month for the foreseeable future until I get my 2% PCE which I have talked about so often."
What are the chances? Zero.
Where is Paul Volcker when you need him?
Gonna be a wild ride. Reply
Bristol-Myers, ImClone, Genentech Release Promising Data at ASCO [view article]
Pharma,that makes more sense, yeah. The Canadian doc. mentioned the costs... I guess it was because of the negotiations you mentioned. OK. Reply
Bristol-Myers, ImClone, Genentech Release Promising Data at ASCO [view article]
AX,"Also we must not forget that when Mike Huckman asked at the ASCO the doctors if they would prescribe Erbitux to their patients the vast majority said yes. And the one that wasn't sure was from Canada."
It is important to mention that Erbitux is not available in Canada. Bristol (who does Erbitux marketing in North America) is still negotiating with Canadian government Erbitux's price sold there. Reply
Bristol-Myers, ImClone, Genentech Release Promising Data at ASCO [view article]
It is a pity that not also is commented on the 3 encouraging clinical trials of Genvec for :1. pancreatic tumor- Phase 3
2. esophageal tumor- Phase 2
3. Head and neck tumor: Phase 1
Genentech is a MegaCap company and GNVC is a SmallCap company. Hence, the effect on GNVC s.p. is most likely more significant.
DYODD Reply
Bristol-Myers, ImClone, Genentech Release Promising Data at ASCO [view article]
I agree completely with the post above from pharma... although I am no expert on medical studies. I think the reporting about the new drug Erbitux was just spin. The market and the media wanted to see Genentech drug to look superior.The reports focused only on the 40% that the Erbitux drug doesn't apply too... and no one mentioned the other 60%. When you get a drug that shows superior results on a specific segment of people, there is no doubt that the drug will be prescribed to them.
Also we must not forget that when Mike Huckman asked at the ASCO the doctors if they would prescribe Erbitux to their patients the vast majority said yes. And the one that wasn't sure was from Canada.
Reply
Bristol-Myers, ImClone, Genentech Release Promising Data at ASCO [view article]
Half-truth is bad. It is more bad than lies. But this is exactly what Jason Napodano provides his readers.Yes indeed, in general ITT [intend to treat] patient population adding Erbitux to chemotherapy extended the overall survival rate to 11.3 months from the 10.1 months for chemotherapy alone.
But this is not the entire story. Flex trial patients population included substantially broader spectrum of patients than the Avastin trial Jason Napodano has mentioned.
So let compare apples with apples:
- the Avastin trial #E4599 was conducted exclusively in Adeno-ca lung cancer patients. Addition of Avastin to chemotherapy improved median survival rates from 10.3 months to 12.3 months. Furthermore, cancer patients in Avastin #E4599 trials were ECOG 0-1 [relatively "healthy" patients] compare with more sick FLEX patients with ECOG 0-2.
In these more sick Adeno-ca lung cancer patients, addition of Erbitux to chemotherapy improved median survival from 10.2 months to 12 months. FLEX Erbitux median survival benefits to more difficult to treat lung cancer patients were practically identical to Avastin.
- But it is not all. FLEX ITT patient population also included SCC- lung cancer patients. These cancer patients can NOT be treated by Avastin due to severe life-threatening side-effects. In this lung cancer population, addition of Erbitux to chemotherapy improved median survival from 8.9 months to 10.2 months.
- It is true, Erbitux did not work on Asian patients. Addition of Erbitux to chemotherapy reduced these patients median survival. Erbutux should not be used in Asian lung-cancer patients.
- Avastin and Erbitux belong to two different classes of drugs. Erbitux is a EGFr-drug. It offers substantial clinical benefits to only a select group of patients and no benefits to the rest. By identifying Erbitux-responding patients [like it is done using biomarkers in colorectal cancers], survival benefits offered by Erbitux are much superior to Avastin benefits.
- Finally, the latest Avastin clinical trials in lung cancer failed to show survival benefits. Consequently, effictiviness of Avastin in lung-cancer became an issue.
Reply
Big Pharma Pipelines Failing to Meet Expectations [view article]
I’ll add a comment here. It’s an area that would be very, very easy for analysts to investigate: contact manufacturers, specifically companies that produce material for clinical trials, phases I and II. It takes very little investigation to discover that pilot plants—the plants that produce such material—are full. In fact, pilot plants in contract manufacturers haven’t been as full for over ten years. More significantly, perhaps, is that following a surge of investment in the late 90s, there is much more capacity in the industry today than there was ten or more years ago—by a factor of three or more. While a lot of this capacity in the outsourcing industry appears to be dedicated to emerging pharma, it’s significant in that many of these drugs find there way into the pipelines of major pharmaceutical companies. While the short term pipeline of major pharma looks bad, in the longer term, five plus years, I’d be a lot more sanguine about the recovery of the industry. Replyres
The CAT's Meow - Cramer's Lightning Round (5/14/08) [view article]
retepog I agree... But besides that HOW can you be bearish on YGE when it has a P/E of 1.64 and and a PEG of .40? I really don't thin Cramer knows the techs of YGE and needs to examine it a lot closer ReplyIndustries to Avoid, Industries to Buy [view article]
Your comments re: Medicare Part D...The majority of meds will be generic. The 'takers' with no risks taken, no path to production factories, no indication of what's in their product other than a USP # to 'claim' it's the drug without the brand name.
Kaiser's used generics for years. Mom complained that her generic vicodin was hurting her stomach (can't tolerate aspirin). I had product analyzed: contained aspirin, acetominophen, caffeine; NO narcotic. How many will die, have adverse reactions, lose disease control (seizure disorders, diabetes, hypertension, angina, etc) because NO ONE is monitoring generics or factories.
Anderson Cooper 360 on CNN did story on this last fall, 2007.
Reply
Potential for Huge Profits Awaits Big Pharma Companies [view article]
the last comment is partly correct and partly a fuss. Cisplatin has been generic for many years and there is considerable competition leading to pricing much much below what the post indicated. Additionally, Michigan State University received well in excess of 250 million dollars in royalties for cothe cisplatin and its follow up carboplatin. The innovator at MSU was able to build a institute on his funds. Thus, the innovator was well rewarded while BMS put in hundreds of millions of dollars in the actual pharmaceutical development of the drug and label expansion. Not all drugs arise from federally funded research. Between what is explored in university laboratories and what is developed through targeted research at company labs, drugs arise. ReplyIndustries to Avoid, Industries to Buy [view article]
Whew, narrow views for sure. You have some growing up to do, and a bit more study. ReplyCurrent Yields Makes Bristol Myers Squibb a Buy [view article]
Absent a good review of the strength of the pipeline, i.e., the number phase 3 clinicals and their probabilities of success in terms of substantial revenue in the near to intermediate term, this article fails to add any value. I agree with MD. ReplyCurrent Yields Makes Bristol Myers Squibb a Buy [view article]
You could duplicate this case for any number of drug stocks, including Pfizer, Merck, GlaxoSmithKline, etc. They are all cheap, and they all pay big dividends (especially Pfizer, with close to 6.5%).Steve
magicdiligence.com Reply
Potential for Huge Profits Awaits Big Pharma Companies [view article]
The trouble is, almost all drug discoveries are made by scientists working in university labs or in government funded institutions such as the NIH and NCI.Edward Kennedy's brain cancer will probably help bring to the public's attention the fact that government funding for cancer drug research (for example) has been cut back by about 90% during the last five to ten years, probably because of the expense of the Iraq War. This has shut the big Pharma drug pipeline down to a trickle even though scientists have many, many promising leads.
Big Pharma does not discover new drugs but only "brings them to market" because the government can't do this immensely difficult thing.
Cisplatin for example, which is used to treat many cancers, costs about $5000 per treatment but it can be produced at a fraction of that cost by the government (it is impossible for the government to sell Cisplatin, of course, because that would be socialism.) Many cancer patients need up to four treatments of Cisplatin which costs them or their providers (us) $20,000.
Cisplatin was discovered by a scientist, in 1971, who got a small financial payment for his discovery. The company which markets Cisplatin has had a monopoly since the early 1970's and has made hundreds of millions of dollars of profit from this one drug because it is so difficult for the government to "bring drugs to market."
This excellent "free market" model for research and development might be vulnerable, especially under a Democrat Presidency. Reply
Potential for Huge Profits Awaits Big Pharma Companies [view article]
This is one of the better articles written in easy language for the novice and self directed investor to digest. All of the statements ring true and make sense. Stockbrokers are only interested in getting you in and out of adventures..This buy and hold theory may still prevail. Although it has proven faulty over the past few years. Too many hedge fund managers are in and out on a daily basis making it imposible for the non trader to get a foothold and maintain some equality. I hope to follow up on some of these ideas and hope that others reading this article do well tooo.....apl Reply